Futuristic Transformations in Industrial Cancer Research

About the report: 

-> It is an extensive progress report of industrial cancer R&D in between 2011-18. 

-> All the major events which have some impact on the industry/community are included.

-> Undoubtedly, immuno-oncology are most successful so far. A detailed report is provided.

->The financial details are also included (validated by both primary and secondary market research) along with mention of the promising companies/startups.

-> Special inclusion of the checkpoint inhibitors.

-> Significant drugs in clinical trials are also included.

-> All the significant approved therapies (both new drugs and label expansions) are included.

-> All the approved therapies are also segregated by their major mechanism of action.

-> Finally, five newer tools/technologies are included with their industrial progress in detail.

-> An update of the article will be provided by the end of this year at no price!

# of Pages: 28 (Preview-available, see top-right corner)

Targetted audience: Industry & Academic Researchers, Healthcare Investors, Oncology/Biotech/Pharma Startups, Master's & Ph.D. students 

About Medgenera

Medgenera is a leading global healthcare news and publishing company. It is world’s first 100% advertisement free healthcare industry media led by a student entrepreneur. As a reader’s only platform the source of revenue is the contribution from the readers. Visit https://medgenera.com/ to know more

Please write to contact@medgenera.com for any question/assistance.